Provided by Tiger Trade Technology Pte. Ltd.

Invivyd, Inc.

1.56
+0.03001.96%
Post-market: 1.560.00000.00%19:16 EST
Volume:1.06M
Turnover:1.68M
Market Cap:439.92M
PE:-3.46
High:1.63
Open:1.53
Low:1.52
Close:1.53
52wk High:3.07
52wk Low:0.4600
Shares:282.00M
Float Shares:204.00M
Volume Ratio:0.29
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4515
EPS(LYR):-1.4333
ROE:-67.94%
ROA:-25.84%
PB:4.73
PE(LYR):-1.09

Loading ...

Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE)

TIPRANKS
·
Feb 03

Invivyd Reaches Alignment With US FDA on Phase 3 Trial of VYD2311 for COVID Prevention

MT Newswires Live
·
Feb 03

BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney

Reuters
·
Feb 03

BUZZ-Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines

Reuters
·
Feb 03

Invivyd Aligns With the U.S. FDA on Liberty, a Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

THOMSON REUTERS
·
Feb 03

Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.
·
Jan 27

BUZZ-Invivyd rises after team-up with Olympic skier Lindsey Vonn

Reuters
·
Jan 22

Invivyd announces partnership with ski champion Lindsey Vonn

TIPRANKS
·
Jan 22

Invivyd Partners with Lindsey Vonn to Promote Antibody Education

Reuters
·
Jan 22

Invivyd Announces Partnership With World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

THOMSON REUTERS
·
Jan 22

Invivyd to Launch Mid-Stage Trial for Investigational Antibody on Long COVID

MT Newswires Live
·
Jan 20

Invivyd and Spear Study Group Announce Plan for Phase 2 Study of Vyd2311 for Treatment of Long Covid and Covid Vaccine-Injured Individuals to Commence Mid-2026

THOMSON REUTERS
·
Jan 20

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

TIPRANKS
·
Jan 20

Invivyd Reports Preliminary Q4 Revenue and Launches Phase 3 DECLARATION Trial

Reuters
·
Jan 08

Invivyd Inc - Prelim Q4 2025 Pemgarda Revenue of $17.2 Mln

THOMSON REUTERS
·
Jan 08

Press Release: Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Dow Jones
·
Jan 08

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Dec 24, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Invivyd, US natgas companies, New Era Energy

Reuters
·
Dec 24, 2025

Invivyd Shares Gain 3.8% After Co Starts Late-Stage Trial for Covid Prevention Antibody

THOMSON REUTERS
·
Dec 23, 2025

Invivyd Shares up 2% Premarket After Co Starts Late-Stage Trial for Covid Prevention Antibody

THOMSON REUTERS
·
Dec 23, 2025